Citation: 吴洲鹏, 赵纪春, 马玉奎. 《欧洲血管外科学会(ESVS)2021 年静脉血栓管理临床实践指南》解读. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(2): 165-170. doi: 10.7507/1007-9424.202101019 Copy
1. | Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg, 2020: S1078-5884(20)30868-6. |
2. | Wanhainen A, Verzini F, Van Herzeele I, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg, 2019, 57(1): 8-93. |
3. | Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14. |
4. | Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis, 2009, 28(4): 401-409. |
5. | Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest, 2016, 149(2): 315-352. |
6. | Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20. |
7. | Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480. |
8. | Karande GY, Hedgire SS, Sanchez Y, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther, 2016, 6(6): 493-507. |
9. | Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181. |
10. | Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. J Thromb Haemost, 2016, 14(9): 1696-1710. |
11. | Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234. |
12. | Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340. |
13. | Kelly J, Hunt BJ. The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. J Thromb Haemost, 2003, 1(9): 1888-1896. |
14. | Garcia-Fuster MJ, Fabia MJ, Furio E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178. |
15. | Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis. Thromb Res, 2017, 157: 147-153. |
16. | Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—Systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80. |
17. | Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317. |
18. | Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016, 41(1): 154-164. |
19. | Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187. |
20. | Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80. |
21. | Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis, 2015, 39(3): 367-378. |
22. | Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med, 1996, 334(11): 677-681. |
23. | Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med, 1996, 334(11): 682-687. |
24. | Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev, 2018, (3): CD003076. |
25. | Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ, 2011, 342: d3036. |
26. | Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost, 2004, 2(5): 743-749. |
27. | Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103(20): 2453-2460. |
28. | Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s choice —A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg, 2019, 57(5): 685-701. |
29. | Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv, 2018, 2(7): 788-796. |
30. | Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708. |
31. | Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med, 2017, 376(13): 1211-1222. |
32. | Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367(21): 1979-1987. |
33. | Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012, 366(21): 1959-1967. |
34. | Shaw JR, Douketis J, Le Gal G, et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost, 2019, 17(7): 1171-1178. |
35. | Meissner MH. Duplex follow-up of patients with DVT: does it have clinical significance? Semin Vasc Surg, 2001, 14(3): 215-221. |
36. | Ascher E, Depippo PS, Hingorani A, et al. Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management? Vasc Endovascular Surg, 2004, 38(6): 525-531. |
37. | Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997, 336(6): 393-398. |
38. | Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood, 2016, 127(6): 696-702. |
39. | Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood, 2017, 129(25): 3285-3293. |
40. | Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res, 2018, 164 Suppl 1: S172-S177. |
41. | Siragusa S, Malato A, Saccullo G, et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol, 2011, 86(11): 914-917. |
42. | Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg, 2000, 32(5): 861-869. |
43. | Roumen-Klappe EM, den Heijer M, van Rossum J, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis, 2009, 27(4): 400-405. |
44. | Arpaia G, Cimminiello C, Mastrogiacomo O, et al. Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM. PRE Trial. Blood Coagul Fibrinolysis, 2007, 18(2): 131-137. |
45. | Amin EE, Bistervels IM, Meijer K, et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 2018, 132(21): 2298-2304. |
46. | Kahn SR, Shapiro S, Ducruet T, et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost, 2014, 112(6): 1137-1141. |
47. | Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med, 2004, 141(4): 249-256. |
48. | Ten Cate-Hoek AJ, Amin EE, Bouman AC, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol, 2018, 5(1): e25-e33. |
49. | Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet, 1997, 349(9054): 759-762. |
50. | Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg, 2008, 47(5): 1015-1021. |
51. | Ten Cate-Hoek AJ, Bouman AC, Joore MA, et al. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 2014, 4(9): e005265. |
52. | Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ, 2016, 353: i2691. |
53. | Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565. |
54. | Turner TE, Saeed MJ, Novak E, et al. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open, 2018, 1(3): e180452. |
55. | PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005, 112(3): 416-422. |
56. | Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet, 2012, 379(9810): 31-38. |
57. | Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med, 2017, 377(23): 2240-2252. |
58. | Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol, 2020, 7(1): e40-e49. |
59. | Sharifi M, Bay C, Mehdipour M, et al. Thrombus obliteration by rapid percutaneous endovenous intervention in deep venous occlusion (TORPEDO) trial: midterm results. J Endovasc Ther, 2012, 19(2): 273-280. |
60. | Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation, 2019, 139(9): 1162-1173. |
61. | Kearon C, Gu CS, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost, 2019, 119(4): 633-644. |
62. | Kahn SR, Julian JA, Kearon C, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord, 2020, 8(1): 8-23. |
63. | Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost, 2017, 15(5): 907-916. |
64. | Ferrara F, Meli F, Amato C, et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology, 2006, 57(4): 418-423. |
65. | Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost, 2017, 15(6): 1142-1154. |
66. | Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev, 2020, 4(4): CD013422. |
67. | Decousus H, Quéré I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med, 2010, 152(4): 218-224. |
68. | Di Minno MN, Ambrosino P, Ambrosini F, et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost, 2016, 14(5): 964-972. |
69. | Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg, 1993, 18(1): 70-73. |
70. | Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med, 2010, 363(13): 1222-1232. |
71. | Cosmi B, Filippini M, Tonti D, Avruscio G, et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost, 2012, 10(6): 1026-1035. |
72. | Galanaud JP, Blaise S, Sevestre MA, et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res, 2018, 171: 179-186. |
73. | Duffett L, Kearon C, Rodger M, et al. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost, 2019, 119(3): 479-489. |
74. | Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg, 2003, 37(6): 415-420. |
75. | Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: Perspectives from the GARFIELD-VTE registry. Thromb Haemost, 2019, 119(8): 1365-1372. |
76. | Thiyagarajah K, Ellingwood L, Endres K, et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis. Thromb Res, 2019, 174: 34-39. |
77. | Montiel SF, Ghazvinian R, Gottsäter R, et al. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J, 2017, 15: 26. |
78. | Schastlivtsev I, Lobastov K, Tsaplin S, et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature. Thromb Res, 2019, 181: 24-28. |
79. | Guzzo JL, Chang K, Demos J, et al. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg, 2010, 52(3): 658-662. |
80. | Bosma J, Vahl AC, Coveliers HM, et al. Primary subclavian vein thrombosis and its long-term effect on quality of life. Vascular, 2011, 19(6): 327-332. |
81. | 傅麒宁, 吴洲鹏, 孙文彦, 等. 《输液导管相关静脉血栓形成中国专家共识》临床实践推荐. 中国普外基础与临床杂志, 2020, 27(4): 412-418. |
82. | Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol, 2020, 7(1): e18-e27. |
83. | Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e737S-e801S. |
84. | Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol, 2019, 6(10): e500-e509. |
85. | Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106(2): 401-407. |
86. | Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol, 2016, 27(3): 354-360. |
87. | Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood, 2002, 100(10): 3470-3478. |
88. | Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res, 2015, 136(3): 582-589. |
89. | Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med, 2018, 378(7): 615-624. |
90. | Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost, 2018, 118(8): 1439-1449. |
91. | Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med, 2020, 382(17): 1599-1607. |
92. | Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 2020, 29(1): 37-44. |
93. | Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371. |
94. | Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med, 2019, 171(10): 685-694. |
- 1. Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg, 2020: S1078-5884(20)30868-6.
- 2. Wanhainen A, Verzini F, Van Herzeele I, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg, 2019, 57(1): 8-93.
- 3. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14.
- 4. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis, 2009, 28(4): 401-409.
- 5. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest, 2016, 149(2): 315-352.
- 6. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20.
- 7. Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480.
- 8. Karande GY, Hedgire SS, Sanchez Y, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther, 2016, 6(6): 493-507.
- 9. Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181.
- 10. Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. J Thromb Haemost, 2016, 14(9): 1696-1710.
- 11. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234.
- 12. Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340.
- 13. Kelly J, Hunt BJ. The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. J Thromb Haemost, 2003, 1(9): 1888-1896.
- 14. Garcia-Fuster MJ, Fabia MJ, Furio E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178.
- 15. Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis. Thromb Res, 2017, 157: 147-153.
- 16. Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—Systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80.
- 17. Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317.
- 18. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016, 41(1): 154-164.
- 19. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187.
- 20. Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80.
- 21. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis, 2015, 39(3): 367-378.
- 22. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med, 1996, 334(11): 677-681.
- 23. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med, 1996, 334(11): 682-687.
- 24. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev, 2018, (3): CD003076.
- 25. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ, 2011, 342: d3036.
- 26. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost, 2004, 2(5): 743-749.
- 27. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103(20): 2453-2460.
- 28. Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s choice —A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg, 2019, 57(5): 685-701.
- 29. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv, 2018, 2(7): 788-796.
- 30. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.
- 31. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med, 2017, 376(13): 1211-1222.
- 32. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367(21): 1979-1987.
- 33. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012, 366(21): 1959-1967.
- 34. Shaw JR, Douketis J, Le Gal G, et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost, 2019, 17(7): 1171-1178.
- 35. Meissner MH. Duplex follow-up of patients with DVT: does it have clinical significance? Semin Vasc Surg, 2001, 14(3): 215-221.
- 36. Ascher E, Depippo PS, Hingorani A, et al. Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management? Vasc Endovascular Surg, 2004, 38(6): 525-531.
- 37. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997, 336(6): 393-398.
- 38. Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood, 2016, 127(6): 696-702.
- 39. Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood, 2017, 129(25): 3285-3293.
- 40. Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res, 2018, 164 Suppl 1: S172-S177.
- 41. Siragusa S, Malato A, Saccullo G, et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol, 2011, 86(11): 914-917.
- 42. Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg, 2000, 32(5): 861-869.
- 43. Roumen-Klappe EM, den Heijer M, van Rossum J, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis, 2009, 27(4): 400-405.
- 44. Arpaia G, Cimminiello C, Mastrogiacomo O, et al. Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM. PRE Trial. Blood Coagul Fibrinolysis, 2007, 18(2): 131-137.
- 45. Amin EE, Bistervels IM, Meijer K, et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 2018, 132(21): 2298-2304.
- 46. Kahn SR, Shapiro S, Ducruet T, et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost, 2014, 112(6): 1137-1141.
- 47. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med, 2004, 141(4): 249-256.
- 48. Ten Cate-Hoek AJ, Amin EE, Bouman AC, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol, 2018, 5(1): e25-e33.
- 49. Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet, 1997, 349(9054): 759-762.
- 50. Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg, 2008, 47(5): 1015-1021.
- 51. Ten Cate-Hoek AJ, Bouman AC, Joore MA, et al. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 2014, 4(9): e005265.
- 52. Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ, 2016, 353: i2691.
- 53. Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565.
- 54. Turner TE, Saeed MJ, Novak E, et al. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open, 2018, 1(3): e180452.
- 55. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005, 112(3): 416-422.
- 56. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet, 2012, 379(9810): 31-38.
- 57. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med, 2017, 377(23): 2240-2252.
- 58. Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol, 2020, 7(1): e40-e49.
- 59. Sharifi M, Bay C, Mehdipour M, et al. Thrombus obliteration by rapid percutaneous endovenous intervention in deep venous occlusion (TORPEDO) trial: midterm results. J Endovasc Ther, 2012, 19(2): 273-280.
- 60. Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation, 2019, 139(9): 1162-1173.
- 61. Kearon C, Gu CS, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost, 2019, 119(4): 633-644.
- 62. Kahn SR, Julian JA, Kearon C, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord, 2020, 8(1): 8-23.
- 63. Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost, 2017, 15(5): 907-916.
- 64. Ferrara F, Meli F, Amato C, et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology, 2006, 57(4): 418-423.
- 65. Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost, 2017, 15(6): 1142-1154.
- 66. Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev, 2020, 4(4): CD013422.
- 67. Decousus H, Quéré I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med, 2010, 152(4): 218-224.
- 68. Di Minno MN, Ambrosino P, Ambrosini F, et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost, 2016, 14(5): 964-972.
- 69. Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg, 1993, 18(1): 70-73.
- 70. Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med, 2010, 363(13): 1222-1232.
- 71. Cosmi B, Filippini M, Tonti D, Avruscio G, et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost, 2012, 10(6): 1026-1035.
- 72. Galanaud JP, Blaise S, Sevestre MA, et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res, 2018, 171: 179-186.
- 73. Duffett L, Kearon C, Rodger M, et al. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost, 2019, 119(3): 479-489.
- 74. Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg, 2003, 37(6): 415-420.
- 75. Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: Perspectives from the GARFIELD-VTE registry. Thromb Haemost, 2019, 119(8): 1365-1372.
- 76. Thiyagarajah K, Ellingwood L, Endres K, et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis. Thromb Res, 2019, 174: 34-39.
- 77. Montiel SF, Ghazvinian R, Gottsäter R, et al. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J, 2017, 15: 26.
- 78. Schastlivtsev I, Lobastov K, Tsaplin S, et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature. Thromb Res, 2019, 181: 24-28.
- 79. Guzzo JL, Chang K, Demos J, et al. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg, 2010, 52(3): 658-662.
- 80. Bosma J, Vahl AC, Coveliers HM, et al. Primary subclavian vein thrombosis and its long-term effect on quality of life. Vascular, 2011, 19(6): 327-332.
- 81. 傅麒宁, 吴洲鹏, 孙文彦, 等. 《输液导管相关静脉血栓形成中国专家共识》临床实践推荐. 中国普外基础与临床杂志, 2020, 27(4): 412-418.
- 82. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol, 2020, 7(1): e18-e27.
- 83. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e737S-e801S.
- 84. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol, 2019, 6(10): e500-e509.
- 85. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106(2): 401-407.
- 86. Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol, 2016, 27(3): 354-360.
- 87. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood, 2002, 100(10): 3470-3478.
- 88. Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res, 2015, 136(3): 582-589.
- 89. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med, 2018, 378(7): 615-624.
- 90. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost, 2018, 118(8): 1439-1449.
- 91. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med, 2020, 382(17): 1599-1607.
- 92. Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 2020, 29(1): 37-44.
- 93. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371.
- 94. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med, 2019, 171(10): 685-694.
-
Previous Article
The therapeutic effect and mid-term follow-up of 154 patients of multiple valvular surgery through right anterolateral intercostal thoracotomy: A retrospective cohort study -
Next Article
Safety and effectiveness of minimally invasive coronary artery bypass grafting in 143 patients: A propensity-score matching study